Alzheimer’s disease is a burden for patients, care partners, and the healthcare system1

An estimated 5.8 million Americans over the age of 65 are living with dementia due to Alzheimer’s disease. That number is projected to reach 13.8 million by 2050.1

Alzheimer’s Disease Prevalence and Economic Data by State1

Projected Number of Patients: Survey from 2019
In 2020

In 2025
Care Partners*
Value of Unpaid Care*

*State totals may not add to the US total due to rounding.

In 2020, direct costs for Alzheimer’s disease and other dementias are estimated at $305 billion1

Biomarkers can play an important role

Not only will biomarkers such as amyloid beta and tau be essential to patient diagnosis and selection for potential new treatments, but they will also be critical for gauging the effects of treatment.3

Of the ongoing clinical trials of investigational agents targeting the underlying pathophysiology of AD, 52 use amyloid imaging and/or cerebrospinal fluid (CSF) to support the diagnosis, 20 determine the outcome via amyloid imaging, and 10 via tau imaging.3

Is the healthcare system prepared for a changing treatment landscape?

Based on assumptions from a simulated model published in 2017, if a potential disease-modifying intervention were to become available in the future, it is anticipated that there may be some healthcare infrastructure challenges that would need to be addressed.4

Icon for a group of patients
Growing patient volume

If a disease-modifying intervention were approved for MCI due to AD, then potentially millions of patients may need comprehensive clinical assessment and meet eligibility for treatment.

Icon for a physician
Shortage of specialists

Specialist shortage and long wait times could be a challenge for patients receiving treatment.

Icon for diagnostic tools 
Access to diagnostic tools

Access to biomarker testing, such as PET (positron emission tomography), could become a limiting factor.


  1. Alzheimer's Association. Alzheimer’s Association Report: 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16(3):391-460.
  2. Koivunen J. Mild cognitive impairment and early detection of Alzheimer’s disease: a positron emission tomography study. Medica – Odontologica. Turku, Finland: University of Turku; 2011.
  3. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019;5:272-293.
  4. Liu JL, Hlavka JP, Hillestad R, Mattke S. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer’s treatment. Published 2017. Accessed February 24, 2020.

© 2020 Biogen. All rights reserved. 6/20 ALZ-US-0046v2
This site is intended for residents 18 years or older of the United States, Puerto Rico, and US
territories. All trademarks are the property of their respective owners.

This site is intended for US Healthcare Professionals